Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1097
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 997–1008 of 1,097 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Recruiting Not applicable Interventional

NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

NCT04471909
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Interventions
NEXUS Aortic Stent Graft System
Device
Lead sponsor
Endospan Ltd.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting No phase listed Observational

IN.PACT™ AV Access Post-Approval Study (PAS002)

NCT04543539
Site status not listed — check the official record
View directory record Official record
Conditions
Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Interventions
IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort, IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Combination Product
Lead sponsor
Medtronic
Industry
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Recruiting No phase listed Observational

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
Interventions
Observational Protocol
Other
Lead sponsor
European Foundation for Study of Chronic Liver Failure
Other
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Timeline
2021 – 2026
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting No phase listed Observational

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553
Site status not listed — check the official record
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Interventions
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Device · Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531
Site status not listed — check the official record
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
FNP-223, Placebo
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Carlsbad, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Recruiting Not applicable Interventional

Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder

NCT06006637
Status at this site: Recruiting
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cognilum TM: Light Treatment Condition
Device
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New York, New York • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting Phase 2 Interventional

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting Phase 3 Interventional

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291
Site status not listed — check the official record
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Enlicitide Decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
52
States / cities
Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consent for Use of Stored Patient Specimens for Future Testing

NCT00031408
Site status not listed — check the official record
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
Not listed
Enrollment
17,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2027
U.S. locations
62
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting Not applicable Interventional

P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

NCT03438747
Site status not listed — check the official record
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
P-15L Bone Graft, Local autologous bone in a TLIF with Instrumentation
Device · Other
Lead sponsor
CeraPedics, Inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
34
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 5, 2026, 12:05 PM EST
Active, not recruiting Phase 3 Interventional

An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

NCT05367960
Site status not listed — check the official record
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Zatolmilast/ BPN14770
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
9 Years to 45 Years · Male only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Irvine, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 5, 2026, 12:05 PM EST

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.